FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2999035275> ?p ?o ?g. }

• W2999035275 endingPage "1000" @default.
• W2999035275 startingPage "984" @default.
• W2999035275 abstract "S-nitrosylation (SNO), a prototypic redox-based posttranslational modification, is involved in the pathogenesis of cardiovascular disease. The aim of this study was to determine the role of SNO of MLP (muscle LIM protein) in myocardial hypertrophy, as well as the mechanism by which SNO-MLP modulates hypertrophic growth in response to pressure overload.Myocardial samples from patients and animal models exhibiting myocardial hypertrophy were examined for SNO-MLP level using biotin-switch methods. SNO sites were further identified through liquid chromatography-tandem mass spectrometry. Denitrosylation of MLP by the mutation of nitrosylation sites or overexpression of S-nitrosoglutathione reductase was used to analyze the contribution of SNO-MLP in myocardial hypertrophy. Downstream effectors of SNO-MLP were screened through mass spectrometry and confirmed by coimmunoprecipitation. Recruitment of TLR3 (Toll-like receptor 3) by SNO-MLP in myocardial hypertrophy was examined in TLR3 small interfering RNA-transfected neonatal rat cardiomyocytes and in a TLR3 knockout mouse model.SNO-MLP level was significantly higher in hypertrophic myocardium from patients and in spontaneously hypertensive rats and mice subjected to transverse aortic constriction. The level of SNO-MLP also increased in angiotensin II- or phenylephrine-treated neonatal rat cardiomyocytes. S-nitrosylated site of MLP at cysteine 79 was identified by liquid chromatography-tandem mass spectrometry and confirmed in neonatal rat cardiomyocytes. Mutation of cysteine 79 significantly reduced hypertrophic growth in angiotensin II- or phenylephrine-treated neonatal rat cardiomyocytes and transverse aortic constriction mice. Reducing SNO-MLP level by overexpression of S-nitrosoglutathione reductase greatly attenuated myocardial hypertrophy. Mechanistically, SNO-MLP stimulated TLR3 binding to MLP in response to hypertrophic stimuli, and disrupted this interaction by downregulating TLR3-attenuated myocardial hypertrophy. SNO-MLP also increased the complex formation between TLR3 and RIP3 (receptor-interacting protein kinase 3). This interaction in turn induced NLRP3 (nucleotide-binding oligomerization domain-like receptor pyrin domain containing 3) inflammasome activation, thereby promoting the development of myocardial hypertrophy.Our findings revealed a key role of SNO-MLP in myocardial hypertrophy and demonstrated TLR3-mediated RIP3 and NLRP3 inflammasome activation as the downstream signaling pathway, which may represent a therapeutic target for myocardial hypertrophy and heart failure." @default.
• W2999035275 created "2020-01-23" @default.
• W2999035275 creator A5000508027 @default.
• W2999035275 creator A5000786308 @default.
• W2999035275 creator A5002472975 @default.
• W2999035275 creator A5003256823 @default.
• W2999035275 creator A5006822602 @default.
• W2999035275 creator A5011806473 @default.
• W2999035275 creator A5025618652 @default.
• W2999035275 creator A5029546482 @default.
• W2999035275 creator A5030968272 @default.
• W2999035275 creator A5033020983 @default.
• W2999035275 creator A5044682682 @default.
• W2999035275 creator A5045722303 @default.
• W2999035275 creator A5049732456 @default.
• W2999035275 creator A5054355498 @default.
• W2999035275 creator A5054374657 @default.
• W2999035275 creator A5073857013 @default.
• W2999035275 creator A5081122566 @default.
• W2999035275 creator A5081938339 @default.
• W2999035275 creator A5081961820 @default.
• W2999035275 creator A5084927110 @default.
• W2999035275 creator A5090381708 @default.
• W2999035275 creator A5090880694 @default.
• W2999035275 date "2020-03-24" @default.
• W2999035275 modified "2023-10-14" @default.
• W2999035275 title "SNO-MLP (S-Nitrosylation of Muscle LIM Protein) Facilitates Myocardial Hypertrophy Through TLR3 (Toll-Like Receptor 3)–Mediated RIP3 (Receptor-Interacting Protein Kinase 3) and NLRP3 (NOD-Like Receptor Pyrin Domain Containing 3) Inflammasome Activation" @default.
• W2999035275 cites W1479757775 @default.
• W2999035275 cites W1588312796 @default.
• W2999035275 cites W1816404068 @default.
• W2999035275 cites W1925508838 @default.
• W2999035275 cites W1953621264 @default.
• W2999035275 cites W1966485417 @default.
• W2999035275 cites W1968109041 @default.
• W2999035275 cites W1974696081 @default.
• W2999035275 cites W1986283558 @default.
• W2999035275 cites W2003683297 @default.
• W2999035275 cites W2013463725 @default.
• W2999035275 cites W2015298614 @default.
• W2999035275 cites W2019483572 @default.
• W2999035275 cites W2036825242 @default.
• W2999035275 cites W2045408001 @default.
• W2999035275 cites W2102981064 @default.
• W2999035275 cites W2108889347 @default.
• W2999035275 cites W2120242177 @default.
• W2999035275 cites W2140421552 @default.
• W2999035275 cites W2141738274 @default.
• W2999035275 cites W2143341110 @default.
• W2999035275 cites W2146358940 @default.
• W2999035275 cites W2170265226 @default.
• W2999035275 cites W2179358839 @default.
• W2999035275 cites W2231291760 @default.
• W2999035275 cites W2235327112 @default.
• W2999035275 cites W2415715899 @default.
• W2999035275 cites W2471101511 @default.
• W2999035275 cites W2481564434 @default.
• W2999035275 cites W2489489141 @default.
• W2999035275 cites W2570109500 @default.
• W2999035275 cites W2607510433 @default.
• W2999035275 cites W2615027571 @default.
• W2999035275 cites W2615980447 @default.
• W2999035275 cites W2616187808 @default.
• W2999035275 cites W2733300123 @default.
• W2999035275 cites W2748400555 @default.
• W2999035275 cites W2756894029 @default.
• W2999035275 cites W2765141222 @default.
• W2999035275 cites W2767041448 @default.
• W2999035275 cites W2776360923 @default.
• W2999035275 cites W2790679145 @default.
• W2999035275 cites W2801761827 @default.
• W2999035275 cites W2801870457 @default.
• W2999035275 cites W2885002489 @default.
• W2999035275 cites W2897240938 @default.
• W2999035275 cites W2903717044 @default.
• W2999035275 cites W2939471759 @default.
• W2999035275 cites W2952011218 @default.
• W2999035275 cites W2982367920 @default.
• W2999035275 doi "https://doi.org/10.1161/circulationaha.119.042336" @default.
• W2999035275 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31902237" @default.
• W2999035275 hasPublicationYear "2020" @default.
• W2999035275 type Work @default.
• W2999035275 sameAs 2999035275 @default.
• W2999035275 citedByCount "39" @default.
• W2999035275 countsByYear W29990352752020 @default.
• W2999035275 countsByYear W29990352752021 @default.
• W2999035275 countsByYear W29990352752022 @default.
• W2999035275 countsByYear W29990352752023 @default.
• W2999035275 crossrefType "journal-article" @default.
• W2999035275 hasAuthorship W2999035275A5000508027 @default.
• W2999035275 hasAuthorship W2999035275A5000786308 @default.
• W2999035275 hasAuthorship W2999035275A5002472975 @default.
• W2999035275 hasAuthorship W2999035275A5003256823 @default.
• W2999035275 hasAuthorship W2999035275A5006822602 @default.
• W2999035275 hasAuthorship W2999035275A5011806473 @default.
• W2999035275 hasAuthorship W2999035275A5025618652 @default.
• W2999035275 hasAuthorship W2999035275A5029546482 @default.
• W2999035275 hasAuthorship W2999035275A5030968272 @default.
• W2999035275 hasAuthorship W2999035275A5033020983 @default.

• next